The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://elodiecggm848761.like-blogs.com/38647144/retatrutide-vs-tirzepatide-a-comparative-analysis